Hemorrhoids medical therapy

Hemorrhoids Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hemorrhoids from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hemorrhoids medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hemorrhoids medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hemorrhoids medical therapy
CDC on Hemorrhoids medical therapy
Hemorrhoids medical therapy in the news
Blogs on Hemorrhoids medical therapy
Directions to Hospitals Treating Hemorrhoids
Risk calculators and risk factors for Hemorrhoids medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Ahmed Younes M.B.B.CH [3]

Overview

Medical (non-procedural) therapy is the appropriate initial management for symptomatic hemorrhoidal disease of all grades and is often definitive for grade I–II internal hemorrhoids. Increased dietary fiber and fluid intake with correction of defecation habits is first-line therapy with the strongest supporting evidence; it reduces persistent symptoms and bleeding but does not improve prolapse, pain, or pruritus. Topical preparations are low-risk symptomatic adjuncts supported only by low-quality evidence. Oral flavonoid phlebotonics reduce bleeding, pruritus, and discharge in randomized trials, but symptoms frequently recur after discontinuation and these agents are not FDA-approved in the United States. Patients who fail an adequate trial of medical therapy, or who have high-grade prolapse, should be referred for office-based procedures or surgery.

Medical Therapy

Candidates for Medical Therapy

• Asymptomatic hemorrhoids require no treatment.
• Conservative/medical therapy is appropriate initial management for all grades and is often definitive for grade I–II internal hemorrhoids and intermittently bleeding disease.
• In grade III–IV internal hemorrhoids, dietary fiber has no meaningful effect on prolapse; medical therapy serves only as a bridge or adjunct to office-based or surgical treatment.

First-Line: Dietary and Behavioral Modification

• Guideline recommendation: Dietary modification with adequate fiber and fluid intake, plus counseling on defecation habits, is primary first-line therapy for symptomatic hemorrhoidal disease (ASCRS; strong recommendation, moderate-quality evidence).
• Treat underlying constipation: Constipation should be evaluated and treated in all patients, as correcting it substantially reduces symptoms. Diarrhea also exacerbates symptoms and should be controlled.
• Fiber: Target 20–30 g/day from fruits, vegetables, and whole grains and/or a supplement such as psyllium.
  • Cochrane meta-analysis (7 RCTs, n=378): fiber reduced the risk of persistent symptoms by 53% (RR 0.47; 95% CI 0.32–0.68) and reduced bleeding (RR 0.50; 95% CI 0.28–0.89).
  • Pooled effects on prolapse, pain, and itching were not statistically significant; mild gastrointestinal adverse effects showed a nonsignificant trend toward increase.
• Fluids: ACG recommends 6–8 glasses of fluid daily; the ASCRS guideline and the 2025 JAMA review cite approximately 5–6 glasses daily.
• Defecation habits: Counsel patients to avoid straining, limit time on the toilet, and avoid reading or phone use on the toilet; these behaviors are associated with symptomatic hemorrhoids.
• Structured behavioral program: In a prospective study of the "TONE" program (≤3 minutes to defecate, once-daily defecation, no straining, enough fiber [5–6 teaspoons psyllium]) in patients with grade III–IV hemorrhoids referred for surgery, prolapse improved in 56.5%, bleeding prevalence fell from 71.8% to 29.4%, and only 12.9% proceeded to surgery.
• Laxatives: For patients who cannot increase dietary fiber, ACG suggests polyethylene glycol 3350 or docusate.

Topical Agents

• Topical creams, ointments, foams, and suppositories carry minimal harm but have only low-quality evidence for symptom relief (ASCRS; conditional recommendation, low-quality evidence).
• They may provide temporary relief of mild bleeding and symptoms and may delay or avoid procedural therapy. Preparations containing hydrocortisone, phenylephrine, or pramoxine may reduce pain and pruritus.
• No high-quality trials establish benefit or compare individual products.

Topical agents for hemorrhoidal disease

Class	Examples	Clinical role	Cautions
Corticosteroids	Hydrocortisone	Most frequently prescribed topical agent (~98% of prescription topicals in a US claims analysis). May reduce perianal inflammation; no evidence of reduced hemorrhoidal swelling, bleeding, or protrusion.	Limit duration; prolonged or high-potency use causes perianal skin atrophy, sensitization, and allergic reactions.
Local anesthetics	Lidocaine 5%, benzocaine, pramoxine	Relieve local pain and pruritus; lidocaine 5% preferred for thrombosed external hemorrhoid presenting >72 hours after onset.	Avoid long-term use (hypersensitization).
Vasoconstrictors	Phenylephrine	Symptomatic relief; low-quality evidence.	-
Astringents	Witch hazel	Symptomatic relief; low-quality evidence.	—

Oral Phlebotonics (Flavonoids)

• Agents: Micronized purified flavonoid fraction (MPFF; diosmin/hesperidin), diosmin, troxerutin, hydroxyethylrutosides, and the synthetic agent calcium dobesilate.
• Proposed mechanism: Increased venous tone, improved lymphatic drainage, and normalized capillary permeability.
• Efficacy: Cochrane review (24 RCTs, n=2334) showed benefit versus placebo/no therapy for bleeding (OR 0.12), pruritus (OR 0.23), discharge/leakage (OR 0.12), and overall symptom improvement, but no significant benefit for pain.
• Consensus position: The Taiwan consensus recommends MPFF to rapidly ameliorate symptoms (moderate-quality evidence, moderate strength) and positions it as an adjunct across all treatment tiers.
• Counseling points:
  • Symptom recurrence approaches 80% within 3–6 months of stopping therapy.
  • Not FDA-approved in the United States; sold as dietary supplements.

Sitz Baths and Local Measures

• Warm sitz baths (~40–42 °C for 10–20 minutes, or brief ~3-minute soaks) are widely recommended for discomfort and sphincter spasm, but evidence of benefit for hemorrhoid pain is lacking.
• Proper anal hygiene and witch hazel–impregnated pads are low-evidence adjuncts.

Thrombosed External Hemorrhoid Presenting After 72 Hours

• Beyond ~72 hours from onset, medical management is preferred over excision: stool softeners, oral and topical analgesics, and topical lidocaine 5%.
• Early excision (within ~48–72 hours) is addressed in the surgery microchapter.

Pregnancy

• First-line: Increased water intake, high-fiber diet with psyllium, stool softeners, avoidance of constipating medications, and warm sitz baths for sphincter spasm.
• Hydrocortisone acetate 1% + pramoxine 1% foam: Improved pain, pruritus, and swelling in late pregnancy without adverse fetal effects in a prospective study of 88 women.
• Compounded sphincter-relaxing ointments: Nitroglycerin 0.125%, nifedipine 0.5%, or diltiazem 2% (± lidocaine 5%), applied three times daily for 1–4 weeks, then twice daily, reduce sphincter spasm and promote healing; these require compounding.
• Topical lidocaine (2.5%–5%) and nifedipine appear safe in pregnancy; avoid long-term anesthetic use.
• Botulinum toxin injection into the internal anal sphincter is an option if ointments fail, used more often for associated anal fissure.

Escalation Beyond Medical Therapy

• Refer grade I–III internal hemorrhoids that fail medical therapy for office-based procedures, with rubber band ligation as first-line procedural therapy.
• Refer for surgical evaluation for persistent bothersome symptoms impairing quality of life despite medical therapy, grade IV disease, large mixed hemorrhoids, strictures, anal mass, or anal pain without a clear source.
• Before attributing rectal bleeding to hemorrhoids, exclude anal fissure, perianal abscess, anal fistula, anal cancer, and anorectal varices, and ensure age-appropriate colorectal cancer evaluation; complete colonic evaluation is indicated in selected patients with symptomatic hemorrhoids and bleeding.

Areas of Uncertainty

• Topical agents: Near-universal use despite persistently low-quality evidence and no comparative trials.
• Flavonoids: Not FDA-approved in the United States; durability of benefit is poor.
• Fluid targets: Differ by source (ACG 6–8 glasses vs. ~5–6 glasses in ASCRS-based recommendations).
• Sitz baths: Recommended by expert consensus without RCT support for pain relief.

Clinical Pearls and Pitfalls

• Correcting constipation and straining is the highest-yield intervention; ensure a genuine trial of fiber, fluid, and bowel-habit correction before escalating.
• Fiber improves bleeding and overall symptoms, not prolapse, pain, or itching; set expectations accordingly.
• Avoid prolonged topical corticosteroid use because of perianal skin atrophy and sensitization.
• Do not rely on sitz baths and over-the-counter topicals for high-grade prolapsing disease that requires procedural referral.
• Counsel flavonoid users that symptoms frequently recur within 3–6 months of stopping, and that these products are supplements rather than FDA-approved drugs.